Catalent appoints a new country leader and expands facilities.
Catalent now in its 40th year of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products in the Japanese market and has appointed Tadahiro Matsumura as Country Leader. Based in Catalent’s Tokyo office, Matsumura will be responsible for driving growth through business development activities in Japan and the surrounding region.
In addition, the company has opened a laboratory at its Kakegawa, Japan site to provide proof-of-concept support and feasibility studies for Catalent’s Zydis Orally Dispersible Tablet (ODT) technology and will also expand manufacturing capacity for its OptiGel Micro softgel technology. Zydis ODT is a freeze-dried oral dosage form that disperses in the mouth, requiring no water. The new Zydis laboratories, which will be officially opened as part of the 40th anniversary celebrations in September, is being constructed within the existing 107,000 square-foot Kakegawa facility. Catalent’s OptiGel Micro Technology uses a droplet, streamline flow that results in spherical capsules. These capsules can be sized from 1-7mm, which allows for smaller capsules to be produced when compared to the traditional rotary die process.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.